273 Comparison of the effect of levosimendan, or dobutamin or placebo in chronic low output decompensated heart failure. CAlcium sensitizer or Inotrope or NOne in low output heart failure (CASINO) study

Zairis, Michael N.; Apostolatos, Charalambos S.; Anastassiadis, Filippos A.; Kouris, Nikolaos; Grassos, H.; Sifaki, Maria; Babalis, Dimitris; Foussas, Stefanos

doi:10.1016/s1567-4215(04)90194-4

Cited by 11 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…52 Significant reductions in mortality were also observed with levosimendan compared to dobutamine and/or placebo. 52,53 However, these favorable results could not be reproduced in larger clinical trials. Although it provided symptomatic relief for patients in the Randomized EValuation of Intravenous LeVosimendan Efficacy (REVIVE) I and II trials, levosimendan had no effect on all-cause mortality at 180 days (primary end point) in the survival of patients with acute heart failure in need of intravenous inotropic support (SURVIVE) trial.…”

Section: Investigational Drugs For Acute Hfmentioning

confidence: 99%

Emerging Therapies for Acute and Chronic Heart Failure

Hanigan

DiDomenico

2016

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Although the period from 1953 to 2001 resulted in the approval of more than 30 medications currently used to treat heart failure (HF), few novel drugs have been approved in the last decade. However, the investigational pipeline for HF medications once again appears promising. In patients with chronic heart failure with reduced ejection fraction (HFrEF), ivabradine and valsartan/sucubitril (LCZ696) were recently approved by the US Food and Drug Administration. Both agents have been shown to reduce the risk of cardiovascular death and HF hospitalization. In the treatment of acute HF, serelaxin and ularitide are the farthest along in development. Both agents have demonstrated favorable effects on surrogate end points and preliminary data suggest a possible mortality benefit with serelaxin. Consequently, phase 3 trials are ongoing to evaluate the effect of serelaxin and ularitide on clinical outcomes. Given the poor history of recent investigational acute HF drugs that have advanced to phase 3/4 studies, enthusiasm for both serelaxin and ularitide must be tempered until these trials are completed.

show abstract

Section: Investigational Drugs For Acute Hfmentioning

confidence: 99%

Emerging Therapies for Acute and Chronic Heart Failure

Hanigan

DiDomenico

2016

Journal of Pharmacy Practice

View full text Add to dashboard Cite

show abstract

“…The CAlcium Sensitizer or Inotrope or NOne in low-output heart failure study (CASINO) is a randomized, double-blind, double-dummy and parallel-group study (20). This study was designed to compare the safety and effi cacy of levosimendan, dobutamine and placebo in patients with decompensated heart failure.…”

Section: Mechanism Of Effectsmentioning

confidence: 99%

A promising new inotrope: levosimendan

Fotbolcu¹,

Duman²

2010

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

“…This agent has a dual mechanism of action: it enhances calcium myofi lament responsiveness by binding to cardiac troponin C, thereby increasing contraction, and opens adenosine triphosphate-sensitive potassium channels in myocytes and vascular smooth muscle cells, promoting vasodilation [45]. Several clinical studies have indicated that levosimendan may reduce mortality compared with current therapy for AHFS [46][47][48].…”

Section: Levosimendanmentioning

confidence: 99%

Pharmaceutical management of decompensated heart failure syndrome in children: Current state of the art and a new approach

Gazit

Oren²

2009

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

Prompt initiation of appropriate and intensive treatment in children with decompensated heart failure is crucial to avoid irreversible end-organ dysfunction. Initial management of these children includes transfer to the pediatric cardiac intensive care unit, basic hemodynamic monitoring, and establishment of intravenous access. Inotropic support should be instituted peripherally before obtaining central venous and arterial access. The team should be prepared for emergent intubation and initiation of mechanical circulatory support. Two experienced physicians should work together to obtain vascular access and manage sedation, airway control, and cardiovascular support. Acute heart failure syndrome in children may be related to cardiomyopathy, myocarditis, congenital heart disease, and acute rejection post heart transplantation. Each of these causes requires a different approach. Fulminant myocarditis may lead to severe morbidity and requires intensive support, although its outcome is considered to be good. Acute heart failure related to newly diagnosed dilated cardiomyopathy may represent end-stage heart failure; therefore, long-term mechanical circulatory support and heart transplantation may be considered to avoid other end-organ dysfunction. Hypertrophic cardiomyopathy may lead to acute decompensation due to 1) left ventricular outflow obstruction, 2) restrictive physiology leading to pulmonary hypertension, or 3) myocardial ischemia associated with coronary artery bridging. Decompensated heart failure associated with congenital heart disease usually represents end-stage heart failure and requires thorough evaluation for heart transplantation. Children with single-ventricle physiology who develop decompensated heart failure after a Fontan procedure are not candidates for mechanical circulatory support and therefore may not survive to heart transplantation. Acute heart failure due to posttransplantation acute rejection requires aggressive antirejection treatment, which places these patients at significant risk for overwhelming opportunistic infections. In our opinion, mechanical circulatory support should be initiated early in children who present with end-stage heart failure associated with hemodynamic instability to avoid end-organ damage.

show abstract

273 Comparison of the effect of levosimendan, or dobutamin or placebo in chronic low output decompensated heart failure. CAlcium sensitizer or Inotrope or NOne in low output heart failure (CASINO) study

Cited by 11 publications

References 0 publications

Emerging Therapies for Acute and Chronic Heart Failure

Emerging Therapies for Acute and Chronic Heart Failure

A promising new inotrope: levosimendan

Pharmaceutical management of decompensated heart failure syndrome in children: Current state of the art and a new approach

Contact Info

Product

Resources

About